Skip to main content
. Author manuscript; available in PMC: 2023 Dec 1.
Published in final edited form as: Adv Drug Deliv Rev. 2022 Nov 11;191:114619. doi: 10.1016/j.addr.2022.114619

Figure 5.

Figure 5

Focused ultrasound and interleukin-4 receptor mediated BBB penetration of liposomes for glioblastoma multiforme therapy. (A) Schematic illustration of receptor and FUS enhanced BBB penetration of DOX loaded liposome and superior anti-brain tumor. (B) Schematic illustrating the preparation of DOX loaded AP-1 conjugated liposomes. Measurements of Lipo-Dox and AP-1 Lipo-Dox in the brain tumor (C) and contralateral normal brain regions (D) with or without sonication. (E) Immunocytochemistry staining of brain tumor to evaluate the distribution of Lipo-Dox and AP-1 Lipo-Dox in glioma xenografts with/without FUS. (F) Bioluminescence imaging of glioma xenografts in different treatment groups to evaluate the anti-tumor efficiency. (G) Representative T2-weighted magnetic resonance imaging of glioma xenografts in the brain in different treatment groups. (H) Relative tumor growth trend of GMB 8401 glioma xenografts in different treatment groups (relative to day 5). (I) Kaplan–Meier survival plot of GBM-bearing mice in different treatment groups. Adapted with permission from ref. [137].